|
IAVI任命Margaret McGlynn为总裁兼首席执行官
来源:美国商业资讯作者:佚名时间:2011-7-8 15:46:51 纽约--(美国商业资讯)--国际艾滋病疫苗倡议组织(IAVI)欣然宣布，任命Margaret (Margie) McGlynn为总裁兼首席执行官。自2010年7月起担任IAVI董事会成员的McGlynn将接替IAVI创始总裁兼首席执行官Seth Berkley。她将与董事会紧密协作，以其深谋远见和领导能力带领IAVI继续前进，并将领导高级管理团队监督该组织的全球业务、计划与合作关系，同时保证其财务稳定性。身为IAVI的领导人，McGlynn将负责在IAVI内部营造一个追求创新与灵活，并积极鼓励合作的氛围，同时坚持不懈地致力于和那些受到艾滋病最严重影响的国家中的研究人员、政府和团体积极接触。出任总裁兼首席执行官的McGlynn将担任IAVI董事会当然成员。
董事会主席Paul Klingenstein表示：“IAVI董事会认为Margie是领导组织发展的不二人选。作为默克(Merck)全球疫苗与抗感染部门前任总裁，Margie在疫苗及HIV领域都有着丰富的经验，对全球健康、公共政策和发展问题有着深入的理解，同时也具备出色的商业才能。”
在担任默克疫苗与传染病业务主管期间，McGlynn曾负责70亿美元的产品组合，并管理了几种重要新疫苗和抗感染制剂的推出，其中包括首个用于预防宫颈癌的疫苗Gardasil，以及首个用于治疗艾滋病病毒的整合酶抑制剂Isentress。在默克任职的26年间，McGlynn曾帮助推出几项计划，让发展中国家的人们能够获得默克的疫苗和抗逆转录病毒药物。此外，她在组建MSD-Wellcome Trust Hilleman Laboratories的过程中也立下了汗马功劳，这家由默克和惠康基金会(Wellcome Trust)在印度合作建立的研究中心专门为发展中世界开发疫苗。
McGlynn表示：“我一直坚持不懈地帮助发展中世界的人们获得挽救生命的药物和疫苗，我很高兴能够出任IAVI首席执行官一职，借此我将能够为寻找有效的艾滋病疫苗做出自己的贡献，终有一天让所有有需要的人们获得这种疫苗。能够领导IAVI，并与我们的合作伙伴携手，进一步巩固当前艾滋病疫苗研究的复兴，我倍感振奋。我期待着与董事会和高级领导团队紧密协作，带领IAVI完成其伟大使命。”
目前，McGlynn还担任多家非营利性和私有领域实体的董事会成员。她曾是致力于帮助发展中世界的人们获得免疫药物，抗击普通传染病的组织——全球疫苗免疫联盟(GAVI Alliance)——的董事会和执行委员会成员，并且曾是国际战略研究中心(Center for Strategic and International Studies)为其全球卫生策略委员会(Commission on Smart Global Health Policy)而招募的25位委员其中之一，该委员会于2010年发布报告，就美国全球卫生举措的长期战略方法向奥巴马政府和国会提供建议。从默克退休后，McGlynn一直致力于支持有关一种影响其家族的罕见遗传疾病的潜在新疗法的研究工作。
IAVI创始人、全球疫苗免疫联盟首席执行官Seth Berkley表示：“Margie的热情、经验和对技术的理解将带领IAVI迈向新的发展阶段。我坚信，在为艾滋病疫苗研发工作而不懈努力的过程中，IAVI将继续发挥其重要的影响力，能够将工作交给Margie这样拥有出色才干和丰富经验的人，我感到非常放心。我期待着未来IAVI能够取得辉煌的成绩。”
McGlynn拥有纽约州立大学水牛城分校(State University of New York at Buffalo)制药学学士学位和营销MBA学位。
关于IAVI
IAVI是一家全球非营利性组织，致力于确保研发出安全、有效、普及的预防性HIV疫苗，在全世界推广使用。IAVI创立于1996年，与25个国家的合作伙伴携手，共同研究、设计和开发艾滋病候选疫苗。此外，IAVI还积极开展政策分析，并大力提倡和推广艾滋病疫苗。IAVI力求以一种全面的方法解决HIV和艾滋病问题，在扩大巩固现有HIV防治项目以及针对性地对新型HIV预防工具的设计研发进行投资之间实现平衡。IAVI致力于保证今后让所有有需要的人们都能够获得艾滋病疫苗。IAVI有赖于政府、私人、企业和基金会的慷慨捐助以履行其使命。垂询详情，请访问：www.iavi.org。
联系方式：
国际艾滋病疫苗倡议组织
Sara Levy, 212-328-7415
[email protected]
艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复 艾滋病不治会早死，早治才康复
 |
| 图示∶2011年5月正式出版的《中国特色医疗金鉴》登载的刘君主任及其机构事迹 |
| |
|
|
IAVI for the appointment of Margaret McGlynn, president and CEO
Source: Business Wire Author: Anonymous Time :2011 -7-8 15:46:51 NEW YORK - (BUSINESS WIRE) - International AIDS Vaccine Initiative (IAVI) is pleased to announce the appointment of Margaret (Margie) McGlynn as President and Chief Chief Executive Officer. Since July 2010 has served as board member of IAVI IAVI McGlynn will succeed founding President and CEO Seth Berkley. She will work closely with the Board, with its dark vision and leadership to seek to move forward to lead the IAVI, and will lead the senior management team to oversee the organization's global operations, plans and partnerships, while ensuring its financial stability. As IAVI leaders, McGlynn will be responsible for IAVI to create an internal pursuit of innovation and flexibility, and encourage cooperative atmosphere, and an unwavering commitment to those most severely affected by AIDS in the country researchers, government and community positive contact. President and CEO of IAVI McGlynn will serve as ex officio member of the board of directors.
Chairman of the Board Paul Klingenstein, said: "IAVI Board of Directors that Margie is the best choice to lead the development of the organization as Merck (Merck) Global Alliance for Vaccines and anti-infection department former president, Margie and HIV vaccine has extensive experience in the field of global health , public policy and a strong understanding of development issues, but also have excellent business acumen. "
Merck vaccines and infectious diseases in the business as an executive in, McGlynn was responsible for 70 billion portfolio, and management of several important new vaccines and the introduction of anti-infective agents, including the first cervical cancer vaccine for the prevention of Gardasil, and the first for the treatment of HIV integrase inhibitor Isentress. Merck worked in 26 years, McGlynn has helped launch several programs, so that people in developing countries have access to Merck's vaccines and antiretroviral drugs. In addition, she formed MSD-Wellcome Trust Hilleman Laboratories in the process also achieved a lot, this by Merck and the Wellcome Foundation (Wellcome Trust) to establish cooperation in the research center in India specifically for the developing world, development of vaccines.
McGlynn said: "I have been consistently helping the developing world access to life-saving drugs and vaccines, I am pleased to be able to post as CEO of IAVI, I will be able to find an effective AIDS vaccine to make their own contribution, one day all people in need receive the vaccine. can lead IAVI, and with our partners to further strengthen the current revival of AIDS vaccine research, I'm thrilled and I look forward to working with the board of directors and senior leadership close collaboration with the team, led IAVI to complete their great mission. "
Currently, McGlynn also served many nonprofit and private sector entities, the Board of Directors. She was committed to helping the developing world's access to immunization drugs against common infectious diseases of the organization - the Global Alliance for Vaccines and Immunization (GAVI Alliance) - Board of Directors and the Executive Committee, and was the CSIS (Center for Strategic and International Studies) for its global health strategy committee (Commission on Smart Global Health Policy) and recruited one of 25 members, the committee released a report in 2010, the U.S. Global Health Initiative's long-term strategic approach to Obama Government and Congress to provide advice. After retiring from Merck, McGlynn has been committed to support the family that affects their rare genetic disease research potential new therapies.
IAVI founder and CEO of the GAVI Alliance Seth Berkley, said: "Margie's enthusiasm, experience and understanding of technology will lead IAVI to a new stage of development, I believe, for the AIDS vaccine research and development and make unremitting efforts in the process in, IAVI will continue to play its important influence on the ability to work with such great talent to Margie and experienced people, I feel very at ease and I look forward to future IAVI can achieve brilliant results. "
McGlynn has a New York State University at Buffalo (State University of New York at Buffalo) pharmacy degree and MBA in marketing.
About IAVI
IAVI is a global non-profit organization committed to ensuring the development of a safe, effective, universal preventive HIV vaccine in the world to promote the use. IAVI was founded in 1996, with 25 national partners work together to research, design and development of AIDS vaccine candidates. In addition, IAVI is also active in policy analysis, and to advocate for and promote the AIDS vaccine. IAVI seeks to address in a comprehensive approach to HIV and AIDS issues in the expansion and consolidation of existing HIV prevention programs targeted for the design of new HIV prevention tools to achieve a balance between R & D investment. IAVI is committed to ensuring the future for all people in need have access to HIV vaccines. IAVI depends on the government, private, business and foundations to contribute generously in order to fulfill its mission. For more information, please visit: www.iavi.org.
Contact:
International AIDS Vaccine Initiative
Sara Levy, 212-328-7415
[email protected]
|
